Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
carrelizumab + TCb
- Development stage
- Unknown
- Lead developer
- Hengrui Pharmaceutical
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
Carrelizumab + TCb is a combination therapy used in oncology, particularly for the treatment of certain cancers. Carrelizumab is a monoclonal antibody that targets the programmed cell death protein 1 (PD-1) receptor on T cells, functioning as an immune checkpoint inhibitor to enhance anti-tumor immune responses. "TCb" refers to a chemotherapy regimen consisting of paclitaxel (T), carboplatin (C), and sometimes another agent such as bevacizumab or trastuzumab depending on context; however, most commonly in Chinese clinical practice and literature, "TCb" denotes paclitaxel plus carboplatin. The combination leverages both immunotherapy (carrelizumab) and cytotoxic chemotherapy (TCb) to improve cancer cell killing by both direct cytotoxic effects and immune-mediated mechanisms.
- Brand names
- AiRuiKa
- Other names
- carrelizumab plus TCbcarrelizumab and TCb
02
Targets
DNATUBB (Tubulin (alpha and beta subunits))PDCD1 (Programmed cell death protein 1 receptor)
Beyond the preview
Go deeper on carrelizumab + TCb.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on carrelizumab + TCb.